posted
Jerm...the way I see it,since the deal has been pretty recent(August)and they set the deal at .20 a share,that tells me this dip is going to be quite temporary and should be taken advantage of.In order to create a more fluid PPS this stock is a great candidate for a forward split,it seems everything is in perfect order just for that.Now wouldn't that be nice...snatch up a couple 100k this week and then they file a pre14 requesting a FS of maybe 3 for 1 or maybe 5 for 1? Only speculating here and have no inside information to sustain this theory.
the Company had 37,561,205 shares of common stock issued and outstanding, of which 21,772,737 were held by non-affiliates. (think about these low numbers!,this could take off like BIPH did! Been reading the most recent 10K, thought I'd share some of my favorite quotes:
1. "The company believes that it will report a net profit for 2005."
2. Regarding LifeStem's stem cell banking service: "It is not unreasonable to project potential revenues approaching $100 Million within 36 to 48 months with as few as 10,000 clients."
3. Officers and Directors:
James DeOlden, Esq. -- CEO: B.A. from UVA, J.D. from Whittier Law School, he has a securities law practice.
Edward Deese -- President, COO: B.S. in Economics from University of California, Irvine.
John Gordon, Ph.D. -- CTO: B.Sc. Honors in Cell Biology, Ph.D. from University of Glasgow.
4. Scientific Advisory Board:
Kary B. Mullis: Recieved the 1993 Nobel Prize in chemistry for his invention of the polymerase chain reaction (PCR). Ph.D. from Berkeley, B.S. from Georgia Institute of Technology.
Basically, the company looks like it's going to be profitable soon and the directors and advisors appear to be very intelligent people who are leaders in their respective fields.
CalbaTech is focused on developing and providing products and platforms to the research market, both for biotech and pharmaceutical companies, as well as academic institutions. In addition to growth through acquisition, CalbaTech, comprised of three divisions, Molecular Applications, Research Reagents, and Cellular Therapeutics, is building an experienced and innovative scientific staff, including several notable members of its Scientific Advisory Board, that intend to contribute innovation in areas of biological discovery.
Contact: Paul Knopick (949) 707-5365 pknopick*eandecommunications.com
CalbaTech now looks to build a portfolio by buying companies that develop new technologies to sell or license; it also targets universities that are planning to license technology developed in academic labs. The firm is interested in products that will generate sales or licensing revenue within two years and need less than $1 million. Among its acquisitions are MolecularWare and iStem Technologies
MoleculareWare helps scientists have the wherewithal to keep their As, Cs, Gs, and Ts straight. The firm, a subsidiary of CalbaTech, offers bioinformatics software and other products to integrate the volumes of data produced from high throughput screening, combinatorial synthesis, and other methods of genomics research. Its DigitalGENOME suite consists of three software programs. DesignerDG can configure microplates and track the liquids used in the microplate wells. AnalyzerDG analyzes images and manages data from microarrays; the software can be used as part of DigitalGENOME or on its own. IntegratorDG can integrate data stored in a variety of database platforms, including platforms from Oracle and Microsoft.
CalbaTech, Inc., (CLBE) said its wholly owned subsidiary, K-D Medical, Inc., Columbia, Maryland, is acquiring a new facility that has two validated, Class 100 Clean Rooms for additional manufacture of products.
K-D Medical is a primary vendor to the National Institutes of Health (NIH) and currently sells products to every major pharmaceutical company in the U.S. K-D Medical's founder, John Powers, said the new Clean Rooms, plus a complete quality control laboratory, will allow the company to manufacture a higher quality product as well as expand the current custom product offering, better serving the needs of both existing and new customers.
"This is a very good position for us, as we increase sales to the National Institutes of Health, major universities and pharmaceutical companies," Powers said.
"These new facilities allow K-D Medical to open new manufacturing and Clean Room leasing opportunities with pharmaceutical and other companies, opportunities that did not exist prior to this," said James DeOlden, chairman and CEO, CalbaTech. "We are very bullish on our subsidiary's future."
This article was prepared by Biotech Week editors from staff and other reports. Copyright 2005, Biotech Week via NewsRx.com.
NewsRx.com) -- CalbaTech, Inc., (CLBE) has retained the services of Agora Investor Relations Corp. (Agora).
The objective of this agreement is two-fold. First, to create effective communication between CalbaTech, its shareholders and the investment community through Agora's Internet based investor relations system. Effective immediately, a customized and monitored CalbaTech IR HUB will allow both CalbaTech and Agora to communicate with all investors simultaneously, anytime and in real-time, while providing shareholders with equal access and complete transparency to all investor relations communications.
The IR HUB will also provide one-click access to the CalbaTech broker fact sheet, company profile, five most recent press releases, e-mail list registration, latest stock quote and chart information and an executive audio address updated quarterly. In addition, the IR HUB provides investors with a monitored discussion forum for the purposes of constructive and high-quality discussion about the company that is free of spam, bashing, hyping and profanity.
Second, Agora will be fully responsible for creating, implementing and executing an investor relations strategy, the consolidation of which will save management a considerable amount of time, effort and expense, allowing them to focus on core business operations, while significantly improving shareholder communications.
CalbaTech CEO James DeOlden stated, "We believe that the time is right to begin an investor awareness program. CalbaTech has been executing its business plan, and given the company's recent developments and the excitement being generated in the life sciences Industry, we believe the time has now come to significantly increase our communications with shareholders and the investment community."
This article was prepared by Biotech Week editors from staff and other reports. Copyright 2005, Biotech Week via NewsRx.com.
posted
CalbaTech's business strategy is establish shareholder value by creating a significant new niche market by providing research reagents, equipment and services to the pharmaceutical research market, primarily through acquisition of life science companies that share the following attributes: 1) They will be generating revenues; 2) They will be profitable; and 3) They will be suppliers of products and services into the pharmaceutical research market. Rather than produce pharmaceutical products that require more than $100 Million to reach the marketplace, CalbaTech companies will seek to provide the products and services used by the researchers creating pharmaceutical products.
"The company reported that its outside patent counsel has conducted a preliminary patent review of the concepts and has reported favorable findings to CalbaTech's management. LifeStem, Dr. Van Tassel and outside counsel will work to further refine the intellectual property and expect to file provisional patents with the United States Patent Office".
Also the fact that the stock ran to .20 in july, expenses static around 1-mil, and this news out Thurs., is significiant, only it may take a few weeks for everyone to sort out.
posted
They have not openly pin pointed any specific virus or biological issue by name yet but take a good hard look at the divisions and with Avian on the top burner right now and the U.S. government announced last week that all companies including small biotechs will and should be researching a vaccine for this flu.
CalbaTech is focused on developing and providing products and platforms to the research market, both for biotech and pharmaceutical companies, as well as academic institutions. It is concentrating on acquiring, incubating and developing life science based companies that are developing current and future generation products and technologies, both in the United States and in the United Kingdom. In addition to growth through acquisition, CalbaTech, comprised of three divisions, Molecular Applications, Research Reagents, and Cellular Therapeutics, is building an experienced and innovative scientific staff, including several notable members of its Scientific Advisory Board that intend to contribute innovation in areas of biological discovery.
on this thread I gave some phone numbers,its worth making a call.Take a look at this team,they have every bio angle covered.
Ph.D. Biochemistry, UC Berkeley
Dr. Mullis received the Nobel Prize in chemistry in 1993, for his invention of the polymerase chain reaction (PCR). The process, which Dr. Mullis conceptualized in 1983, is hailed as one of the monumental scientific techniques of the 20th century, one that revolutionized genetic science and engineering. PCR has also been an enormous commercial success. The original patent was sold to Hoffman LaRoche for $300 million and has generated more than a billion dollars in revenue from royalties.
Paul Heaney, Ph.D. Ph.D. Medicinal Chemistry, Univ. of Glascow, Scotland
Dr. Heaney has held numerous positions within the life sciences industry, most recently as EVP of Research and Technology at Sequenom. Dr. Heaney's team was responsible for the development of the highly acclaimed and commercially successful chip-based MassARRAY™ Genotyping Platform and the MassARRAY™ 200K which can be multiplexed to more than one million DNA assays per day. While Head of Bioelectronics at the Sarnoff Corporation, Dr. Heaney's team was awarded a $12 million DARPA grant which led to the spin-out of Orchid BioSciences. Dr. Heaney holds more than 25 patents.
David O'Bryan, Ph.D. Ph.D. Medical Sciences/Biochemistry, BU Med School
Dr. O'Bryan is a former Senior VP at SmithKline Beecham Clinical Laboratories. He has more than 28 years experience in the clinical testing industry, including significant experience in developing new technologies. On behalf of SmithKline Beecham Clinical Laboratories he negotiated license agreements involving patented gene sequences used to diagnose diseases and secured the first license for nucleic acid testing. Dr. O'Bryan is also a recognized expert in laboratory instrumentation and automation in the commercial reference laboratory industry.
Gerald Huth, Ph.D. Ph.D. Physics/Electronics, Uppsala University, Sweden
In 1985, Dr. Huth founded Xsirius Scientific, Inc. Two subsidiaries, Xsirius Superconductivity, Inc. and Xsirius Photonics, Inc. had IPOs and traded on NASDAQ, with Xsirius Scientific having a market cap exceeding $100 million.
To learn more about Dr. Huth and his inventions visit www.ghuth.com[/b]
Jason Van Tassel, M.D. Dr. Van Tassel is currently in medical practice specializing in Otolaryngology, Facial Plastic and Reconstructive Surgery in Los Angeles, CA. Dr. Van Tassel attended Georgetown University School of Medicine in Washington D.C., graduating with Honors in 1997. Upon completion of his residency, Dr. Van Tassel joined the faculty at the University of California at Irvine in the Department of Facial Plastic and Reconstructive Surgery, completing a fellowship in 2003. He is currently board certified in Otolaryngology and board eligible in Facial Plastic and Reconstructive Surgery. Prior to practicing medicine in LA, Dr. Van Tassel worked at Hybritech Inc., where he performed research investigating manufacturing processes related to monoclonal antibody test assays. In addition, Dr. Van Tassel also investigated retinal signal transduction pathways for the Dept. of Neurosciences at San Diego State.
John A. Drews, M.D., J.D. Dr. Drews was in the clinical practice of cardiothoracic surgery in CA, from 1976 through 1990 as a member of a medical group which performed cardiac, vascular, and thoracic surgery. During that time Dr. Drews was instrumental in the founding of the Orange Coast Heart Institute at Hoag Hospital, Newport Beach, in 1982 (now the Hoag Heart and Vascular Institute). Dr. Drews has contributed approximately 17 research articles to various prominent medical journals. He is a Fellow of the American College of Surgeons, as well as a member of many other medical surgical societies. Dr. Drews received his bachelor's degree from Duke University in 1963 and his M.D. from Yale University in 1967. He is board certified in both general surgery and cardiothoracic surgery having trained at both UCLA Hospital and Yale-New Haven Hospital in Connecticut. Dr. Drews received his law degree from Western State University College of Law in 1994 and has subsequently performed medico-legal consulting in many medical malpractice case
posted
The way it looks it appears the biotech sector is about to heat up probably equal to the energy sector,between the great advances recently in adult stem cell research now its about to open doors without controversy following behind which really inhibited the same research when extracting embryonic cells and now with the Avian flu predictions that could be catastrophic to say the least I think many labs are working overtime now. I may try to visit one of the CalbaTech divisions in Maryland this week before I head to Florida,if not I'll have to check it out when I get back near the end of Month, its the K-D Medical site...
K-D Medical, Inc. 6935-A Oakland Mills Road Columbia, Maryland USA 21045 (410) 290-9690 (Phone) (410) 290-9691 (Fax)
a lot is going on in this sector and this specific industry so we can expect more PR's from the company imo keeping up us to date and so far fortunately I don't believe we are listed in any foreign markets like Berlin of Frankfurt.
ANKARA, Turkey -- Turkey and Romania culled thousands of birds and imposed quarantine zones on Sunday to try to stop the spread of avian flu as scientists worked to discover if the outbreaks could be the deadly H5N1 strain.
Reports of Turkey's outbreak only surfaced on Saturday night, but nearly 2,000 turkeys died at the affected farm near the Aegean Sea on Tuesday and Wednesday and hundreds more were culled overnight in the affected area, local media said.
Hurriyet newspaper quoted Mehmet Eksen, owner of the stricken farm, as saying he now feared for his own health. Authorities slapped a 3 km (1.8 mile) quarantine ring around the site.
"I cried when I witnessed the death of my turkeys. I cannot forget those moments ... But now I think of myself and what will happen to my health. I cannot go near my wife and children."
The state Anatolian news agency quoted local official Resul Celik as saying: "At the moment this is not a situation which should cause (ordinary citizens) any worry."
Romania's suspected outbreak was detected in poultry in the Danube delta, on the Black Sea, and the European Commission says the two cases are different but they have raised the specter of the disease reaching European Union countries.
If the Romanian cases did turn out to be the deadly H5N1 virus, they would be the first evidence the strain has spread to Europe from Asia, where it has killed more than 60 people and millions of birds since 2003.
Russia and Kazakhstan have already had outbreaks.
Experts fear H5N1 could mutate into a virus which spreads easily among humans, creating a pandemic that might kill millions. The so-called Spanish flu pandemic of 1918 killed between 20 and 40 million people worldwide.
Britain said it was sending a team of experts to Romania to help and was in touch with Turkey authorities. Romania said Britain, which has the European reference laboratory for avian influenza, would deliver "the final verdict" on the birds.
Posts: 1364 | From: Somebody from Europe | Registered: Sep 2005
| IP: Logged |
posted
CalbaTech's Subsidiary, K-D Medical, Inc., Contracts With Independent Sales and Marketing Group to Increase Sales Monday October 10, 5:00 am ET
IRVINE, Calif. and COLUMBIA, Md., Oct. 10 /PRNewswire-FirstCall/ -- CalbaTech, Inc. (OTC Bulletin Board: CLBE - News), an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions, announced today that its wholly owned subsidiary, K-D Medical, Inc., Columbia, Maryland, has contracted with an independent sales and marketing group, Imgen Technologies, to bring its products to new customers with the intention of opening new accounts and increasing sales. ADVERTISEMENT
K-D Medical, a primary vendor of the National Institutes of Health, also currently sells its full line of molecular biology products to Universities, Research Centers and major Pharmaceutical companies nationwide.
Imgen Technologies is an independent sales and support company for innovative molecular biology and life science product manufacturers with extensive experience in increasing sales and locating new customers. The group includes five members who travel from North Carolina to New York to demonstrate and service these product lines. The contract is for two years.
About CalbaTech
CalbaTech, Inc. (OTC Bulletin Board: CLBE - News) is an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions.
About K-D Medical, Inc.
K-D Medical, located in the heart of the Maryland Biotech Corridor, is one of the nation's leading manufacturers of microbiological culture media and other research reagents. K-D Medical's products are used in drug discovery, microbiology labs and biopharmaceutical production. The company is headquartered in Columbia, Maryland.
Contact: Paul Knopick E&E Communications (949) 707-5365 pknopick*eandecommunications.com
Note: Certain statements in this news release may contain "forward-looking" information within the meaning of rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Act of 1934 and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, may include forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will be accurate and actual results and future events could differ materially from those anticipated in such statements.
Posts: 1364 | From: Somebody from Europe | Registered: Sep 2005
| IP: Logged |
A two-day webcast begins Saturday, hosted by BayBio, Northern California's life science association, where the California Institute of Regenerative Medicine (CIRM) will hold its first scientific meeting featuring six scientific sessions with presentations by stem cell researchers and clinicians from the United States, Australia, Canada, Israel, Sweden and the United Kingdom.....link...baybio .org
this and the upcoming releases will play a big roll for CLBE and other stem cell and biotech companies and you can bet institutional interest is growing so if you think its hard to buy now just wait when the big boys step in.
posted
Stem Cell Cure for Peripheral Vascular Disease on the Horizon
Peripheral Vascular Disease is a near-pandemic condition that threatens millions with loss of limb; and also life. PVD is the result of narrowing arteries that deprive regions of the body—typically hands, feet, and limbs—of much-needed blood. Stem cell therapy enables patients’ own bodies to repair damaged blood vessels and grow new ones thus restoring blood flow and oxygen to damaged tissue.
If you have a professional interest in whether embryonic and other forms of stem cell research are supported at the state level, then you should subscribe to State Stem Cell Funding News.
October 2005 Cells From Amniotic Fluid Are Used To Tissue-Engineer A New Trachea Neural Stem Cells Are Long-Lived Hair-Raising Stem Cells Identified New Stem Cell Therapy Research Centers Are Established
posted
MMs just retreated from that .065 ask. Just as I typed this, another one retreated.
No MMs anymore at the .065 ask!!!!!
Now it's 4 MMs at .07.
Must be a lot of demand for this, and this is gonna gap for sure.
I only wish that they'd filled more shares for me on Friday, but they didn't. I'll definitely have an order ready for .07 at the open. Maybe I'll get some more before this baby flies.
posted
I am tellin ya,this has another "BIPH" written all over it,just look at the other stem cell companies now! Don't be surprised to see this at .20 this week imo!
posted
many will see over the next month that this is heading north...far north imo.And once the IR firms kick in they are going to be targeted by institutional thats why most better buy asap because after the big boys step in the shares are gone!
posted
Quest; I would but all my money is tied up with AMEP... I'll keep an eye on it though.
Posts: 76 | From: Miami, Florida | Registered: Oct 2005
| IP: Logged |
posted
take advantage of these dips,many DT's made entries Friday and took profit exits this morning,doubt they get back in again unless they are going to pay higher.I possibly believe this could touch .20's this week before moving to even higher ground following weeks imo.
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Smile]](smile.gif)
